Influential and critical stakeholders such as physicians, patient advocacy groups (PAGs), health technology assessment (HTA) agencies, or thought leaders (TLs) can present a hurdle for developers even after they have satisfied regulators and payers. Many companies are struggling to develop timely communication strategies.
The stakeholder landscape has grown more complex and crowded. Failure to capture second order constituencies in many cases can mean partial adoption, or market failure for new products.
This article looks at how to create effective ways to engage with these constituencies and earn their advocacy for new products.